Automobile sector margins are projected to improve gradually after the second quarter of FY27 as manufacturers increase prices. The growth ...

Coforge shares fell despite strong Q2 results and brokerages raising target prices. Net profit surged 56.5% year-on-year to Rs 588.1 crore,...

IndusInd Bank announced a net profit of Rs 1,176 crore for the quarter ending September 2027. The bank's asset quality improved with gross ...

September quarter earnings exhibited significant revenue and profit growth for various companies in key sectors. Revenue rose by 22.1% with...

Indian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...

Kotak Mahindra Bank has announced an impressive 26% year-on-year increase in consolidated profit after tax for the second quarter, highligh...

"Apple India Private Limited provides and markets Apple brand products and software, and reported its revenues for the financial year 2025-...

The review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a...

In an interview with Kshitij Anand of ETMarkets, Jeet Marwadi, Founder and Managing Director of 1 Finance, explains why reviewing loans, in...

Sun Pharma successfully secured ₹7,816 crore in its latest fundraising round, yet it fell short of its ambitious ₹10,000-crore target. The ...

In a significant legal battle, former office boy Waghela challenged a disputed tax order linked to dubious financial practices. The Income ...

Tata Motors Commercial Vehicles is expected to post strong Q2FY27 revenue and profit growth, driven by 43% volume expansion. However, risin...

Varmora Granito Ltd reported a 498 percent growth in profit after tax for the first half of the fiscal year. They saw a 3.3 percent rise in...

Paresh Bhagat, Chairman of Mangal Keshav Financial Services, discusses where India’s next wealth creators could emerge from, why several mi...

India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...

From a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...

At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...